University of Groningen Paediatric pulmonary hypertension Loon, Rosa Laura Elisabeth van IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2010 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Loon, R. L. E. V. (2010). Paediatric pulmonary hypertension: epidemiology, characterisation and treatment Groningen: s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 15-01-2019
BIBLIOGRAPHY ARTICLES van Loon RLE, Yap YN, Witsenburg M. Idiopatische ventrikeltachycardie bij een adolescent. Tijdschr Kindergeneeskd 2006; 74(5):191-195. Duffels MGJ, Engelfriet PM, Berger RMF, van Loon RLE, Hoendermis ES, Vriend JW, van der Velde ET, Bresser P, Mulder BJM. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol 2007; 120(2):198-204. 203 Duffels MGJ, van Loon RLE, Berger RMF, Boonstra A, Vonk-Noordergraaf A, Mulder BJM. Pulmonary arterial hypertension associated with a congenital heart defect: advanced medium-term medical treatment may improve exercise capacity. Congenital Heart Disease 2007; 2(4):242-249. van Loon RLE, Hoendermis ES, Duffels MGJ, Vonk-Noordegraaf A, Mulder BJM, Hillege HL, Berger RMF. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J 2007; 154(4):776-782. Duffels MGJ, Vis JC, van Loon RLE, Berger RMF, Hoendermis ES, van Dijk AP, Mulder BJM. Down patients with Eisenmenger syndrome: is medical treatment an option? Int J Cardiol 2008; 134(3):378-383. Duffels MGJ, Vis JC, van Loon RLE, Nieuwkerk PT, van Dijk AP, Hoendermis ES, de Bruin- Bon RHACM, Bouma BJ, Bresser P, Berger RMF, Mulder BJM. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down s syndrome. Am J Cardiol 2009; 103(9):1309-1315. van Loon RLE, Roofthooft MTR, van Osch-Gevers M, Delhaas T, Strengers JLM, Backx A, Blom NA, Berger RMF. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatrics 2009; 155(2):176-182. van Loon RLE, Roofthooft MTR, Berger RMF. Pulmonary arterial hypertension in children with congenital heart disease. PVRI review 2009; 1(4):219-223. van Loon RLE, Roofthooft MTR, Delhaas T, van Osch-Gevers M, ten Harkel ADJ, Backx A, Strengers JLM, Hillege HL, RMF Berger. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol 2010; In Press.
OTHER 204 van Loon RLE, Berger RMF (Redactie). Standaard diagnostiek en behandeling van pulmonale hypertensie bij kinderen. Dec 2006. (ISBN 90-811456-1-4) ABSTRACTS Oral presentations van Loon RLE, Roofthooft MTR, van Osch-Gevers M, Delhaas T, Strengers JLM, Backx A, Blom NA, Berger RMF. Outcomes in children with pulmonary arterial hypertension: Dutch experience. Cardiol Young 2007; 17(Suppl 1):10. 42 nd Annual Meeting of the AEPC, Warsaw, Poland. van Loon RLE, Hoendermis ES, Duffels MGJ, Vonk-Noordegraaf A, Mulder BJM, Hillege HL, Berger RMF. Long-term effect of bosentan in patients with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Cardiol Young 2007; 17(Suppl 1):10-11. 42 nd Annual Meeting of the AEPC, Warsaw, Poland. Blom NA, Berger RMF. Uitkomsten van kinderen met pulmonale arteriële hypertensie: Nederlandse ervaring. Tijdschr Kindergeneeskd 2007. 24 e Congres NVK, Veldhoven. Blom NA, Berger RMF. Karakterisering van pulmonale hypertensie op de kinderleeftijd: complexe presentatie en diagnose. Tijdschr Kindergeneeskd 2008. 25 e Congres NVK, Veldhoven. Wijnberg H, Mohaupt S, van Loon RLE, van Albada ME, Bartelds B, Berger RMF. Mestcel gemedieerde pulmonale vaatwand remodellering in flow-geassocieerde pulmonale arteriële hypertensie. Tijdschr Kindergeneeskd 2008. 25 e Congres NVK, Veldhoven. van Loon RLE, Bartelds B, Wagener FADTG, van Albada ME, Affara N, Wijnberg H, Mohaupt S, RMF Berger. Role of heme oxygenase-1 and endothelial progenitor cells in the beneficial effects of erythropoietin on flow-associated pulmonary arterial hypertension. Cardiol Young 2009. 5 th World Congress of PCCS, Cairns, Australia. Poster presentations van Loon RLE, Dalinghaus M, Hop WCJ, Bogers AJJC, Berger RMF. Early and late outcome after different modifications of the Fontan procedure. Cardiol Young 2002; 12(Suppl 1). 37 th Annual Meeting of the AEPC, Porto, Portugal.
van Loon RLE, Hoendermis ES, Duffels MGJ, Vonk-Noordegraaf A, Mulder BJM, Hillege HL, Berger RMF. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Eur Heart J 2007. 42 nd Annual Meeting of the ESC, Vienna, Austria. Blom NA, Berger RMF. Clinical characterization of paediatric pulmonary hypertension: not as straightforward as the Venice Classification. Cardiol Young 2008; 18(Suppl 1):66-67. 43 rd Annual Meeting of the AEPC, Venice, Italy. 205 Blom NA, Berger RMF. Clinical characterization of paediatric pulmonary hypertension: complex presentation and diagnosis. Eur Heart J 2008. 43 rd Annual Meeting of the ESC, München, Germany. Mohaupt S, Wijnberg H, van Loon RLE, van Albada ME, Bartelds B, Berger RMF. Mast cell mediated vascular remodelling in flow-associated pulmonary arterial hypertension. Arch Dis Child 2008. 2 nd Congress of the EAP, Nice, France. Affara N, van Loon RLE, van Albada ME, Bartelds B, Berger RMF. Erythropoietin induces, while heme oxygenase inhibits mobilization of endothelial progenitor cells in flow associated pulmonary arterial hypertension in rats. Arch Dis Child 2008. 2 nd Congress of the EAP, Nice, France. van Loon RLE, Roofthooft MTR, van Osch-Gevers M, Delhaas T, ten Harkel ADJ, Backx A, Strengers JLM, Hillege HL, Berger RMF. Outcome of children with pulmonary arterial hypertension in the era of antiproliferative therapy. Cardiol Young 2009. 5 th World Congress of PCCS, Cairns, Australia. van Loon RLE, Bartelds B, Wagener FADTG, van Albada ME, Affara N, Wijnberg H, Mohaupt S, RMF Berger. Role of heme oxygenase-1 and endothelial progenitor cells in the beneficial effects of erythropoietin on flow-associated pulmonary arterial hypertension. Eur Heart J 2009. 44 th Annual Meeting of the ESC, Barcelona, Spain. van der Horst MB, van Loon RLE, Roofthooft MTR, van Weert E, Hillege HL, Berger RMF. Extension of the 6-minute walk test in children with pulmonary arterial hypertension: value of additional variables such as oxygen saturation, heart rate and Borg score in estimating disease severity and prognosis. Eur Heart J 2009. 44 th Annual Meeting of the ESC, Barcelona, Spain. Douwes JM, van Loon RLE, Hoendermis ES, Talsma M, Berger RMF. Prevalence and prognostic value of acute pulmonary vasodilator response in children and adults with pulmonary arterial hypertension. Eur Heart J 2009. 44 th Annual Meeting of the ESC, Barcelona, Spain.